Clinical trial
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
NCT00422019 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00422019 |
|---|---|
| Title | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma |
| Official title | A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | AMG 102 at 10 mg/kg, AMG 102 at 20 mg/kg |
| Enrollment | 61 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jan 15, 2007 |
| Last update posted | Apr 10, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: